secwatch / observer
8-K filed August 17, 2022, 7:59 PM ET ticker MRNA CIK 0001682852
leadership confidence high sentiment neutral materiality 0.70

Moderna appoints James Mock as CFO effective Sept 6, 2022; David Meline retires

Moderna, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Meline

Chief Financial Officer
MRNA · Moderna, Inc.
Effective
2022-09-06
Successor
James Mock
Filed
August 17, 2022, 7:59 PM ET
David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.
Appointed

James Mock

Chief Financial Officer
MRNA · Moderna, Inc.
Effective
2022-09-06
Filed
August 17, 2022, 7:59 PM ET
James Mock has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning September 6, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Meline departed as Chief Financial Officer at Moderna, Inc..

Action
retire
Role
Chief Financial Officer
Exact text from the filing
David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

James Mock was appointed as Chief Financial Officer at Moderna, Inc..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
James Mock has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning September 6, 2022.
View on SEC.gov

Moderna, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-223286
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.